Victoriana going cheap
An entertainment business covered here, with its roots in the Victorian era, has just reported encouraging results. The shares look good value, but possibly for good reason, as our update here reflects. Elsewhere, there was an encouraging contract win for a business with its eyes on the future. (Free to read)
Bioventix: tough comparator, but solid as always Bioventix (AIM:BVXP), the developer of high-affinity monoclonal antibodies for applications in clinical diagnostics, announced interim results for the six-months to 31 December 2021. Bioventix currently offers a portfolio of antibodies to customers for both commercial use and R&D purposes, for the diagnosis or monitoring of a broad range of conditions, including heart disease, cancer, fertility, thyroid function and drug abuse. It supplies antibody products and services to many multinational clinical diagnostics companies. It’s a highly unusual ‘IP’ business reflected in the very high margins. As the pandemic continued to have an impact on…